Marjolein de Bruin-Weller

Marjolein de Bruin-Weller

Auto-generated profile, based on publicly available information

Marjolein de Bruin-Weller

Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht Utrecht The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2017 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
MBM. de Bruin-Weller
M. de Bruin-Weller
DTDiamant Thaçi
Diamant Thaçi
CSC.H. Smith
C.H. Smith
KRK. Reich
K. Reich
MCM.J. Cork
M.J. Cork
BSB. Shumel
B. Shumel
Background Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side‐effects limit its use. Dupilumab, a fully human anti‐interleukin 4 receptor‐alpha monoclonal antibody, inhibits signaling of IL‐4 and IL‐13, key drivers of Type 2/Th2‐mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately‐controlled moderate‐to‐severe atopic dermatitis in adults. Objectives To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS) in adults with atopic dermatitis with inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. Methods In this 16‐week, double‐blind, randomized, placebo‐controlled, phase III trial, patients were randomized 1 : 1 : 1 to subcutaneous dupilumab 300 mg weekly (qw) or every 2 weeks (q2w) or placebo. All received concomitant medium‐potency TCS from Week −2 through Week 16; dosage could be tapered if lesions cleared, or stopped for adverse reactions to TCS. Results In total, 390 patients were screened, 325 were randomized, and 318 completed the trial. Treatment groups had similar baseline characteristics. Significantly more patients in the dupilumab qw + TCS and q2w + TCS groups achieved ≥ 75% improvement from baseline in the Eczema Area and Severity Index at Week 16 vs. the placebo + TCS group (primary end point) (59·1% and 62·6% vs. 29·6%, respectively; P < 0·001 vs. placebo + TCS, both doses). Other clinical outcomes and atopic dermatitis symptoms were significantly improved in the dupilumab qw + TCS and q2w + TCS groups, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and quality of life (QoL). Treatment groups had similar overall rates of adverse events (qw + TCS, q2w + TCS and placebo + TCS groups: 69·1%, 72·0% and 69·4%, respectively) and serious adverse events (1·8%, 1·9% and 1·9%, respectively). Conjunctivitis was more frequent with dupilumab + TCS; skin infections were more frequent with placebo + TCS. Conclusions Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.

9 March 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
BAB. Akinlade
B. Akinlade
EGE. Guttman‐Yassky
E. Guttman‐Yassky
MBM. Bruin‐Weller
M. Bruin‐Weller
ESE.L. Simpson
E.L. Simpson
ABAndrew Blauvelt
Andrew Blauvelt
AWA. Wollenberg
A. Wollenberg
Background Dupilumab, which blocks the shared receptor component for interleukin (IL)‐4 and IL‐13, is approved for inadequately‐controlled moderate‐to‐severe atopic dermatitis (AD) and moderate‐to‐severe eosinophilic or oral corticosteroid‐dependent asthma. AD trials reported increased conjunctivitis incidence for dupilumab vs. placebo. Objectives To further characterise conjunctivitis occurrence and risk factors in dupilumab clinical trials. Methods We evaluated randomised placebo‐controlled trials of dupilumab in AD (n=2629), asthma (n=2876), chronic rhinosinusitis with nasal polyps (CRSwNP) (n=60), and eosinophilic esophagitis (EoE) (n=47). Results In most AD trials, dupilumab‐treated patients had higher conjunctivitis incidence than placebo controls. Higher baseline AD severity and previous conjunctivitis history were associated with increased conjunctivitis incidence. Conjunctivitis was mostly mild to moderate. Most cases recovered/resolved during the treatment period; 2 patients permanently discontinued dupilumab due to conjunctivitis/keratitis. Common treatments included ophthalmic corticosteroids, antibiotics, and anti‐histamines/mast cell stabilisers. Most cases were diagnosed by investigators. In asthma and CRSwNP trials, conjunctivitis incidence was lower for both dupilumab and placebo than in AD trials; dupilumab did not increase incidence vs. placebo. In the EoE trial, no patients had conjunctivitis. Conclusions Conjunctivitis was more frequent with dupilumab treatment in most AD trials. In dupilumab trials in other type 2 diseases, incidence of conjunctivitis was overall very low, and was similar for dupilumab and placebo. In AD, conjunctivitis incidence was associated with AD severity and prior history of conjunctivitis. The aetiology and treatment of conjunctivitis in dupilumab‐treated patients require further study.

28 January 2018 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ADA.M. Drucker
A.M. Drucker
KEK. Eyerich
K. Eyerich
MBM.S. de Bruin-Weller
M.S. de Bruin-Weller
JTJ.P. Thyssen
J.P. Thyssen
PSP.I. Spuls
P.I. Spuls
EGE. Guttman-Yassky
E. Guttman-Yassky
Guidelines discourage the use of systemic corticosteroids for atopic dermatitis but their use remains widespread. To reach consensus among an international group of atopic dermatitis experts on the use of systemic corticosteroids for atopic dermatitis. A survey consisting of statements accompanied by visual analog scales ranging from “strongly disagree” to “neutral” to “strongly agree” was distributed to the International Eczema Council (IEC). Consensus was reached in agreement on a statement if <30% of respondents marked to the left of “neutral” towards “strongly disagree.” Sixty of 77 (79%) IEC members participated. Consensus was reached on 12 statements, including that systemic corticosteroids should generally be avoided but can be used rarely for severe atopic dermatitis under certain circumstances, including a lack of other treatment options, as a bridge to other systemic therapies or phototherapy, during acute flares in need of immediate relief, in anticipation of a major life event or in the most severe cases. If used, treatment should be limited to short-term. Most respondents agreed that systemic corticosteroids should never be used in children, but consensus was not reached on that statement. The conclusions of our expert group are limited by a dearth of high-quality published evidence. If more stringent consensus criteria were applied (e.g., requiring <20% of respondents marking towards “strongly disagree,” consensus would have been reached on fewer statements. Based on expert opinion from the IEC, routine use of systemic corticosteroids for atopic dermatitis is generally discouraged and should be reserved for special circumstances.

7 May 2019 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
LELawrence F. Eichenfield
Lawrence F. Eichenfield
TBThomas Bieber
Thomas Bieber
LBLisa A. Beck
Lisa A. Beck
ESEric L. Simpson
Eric L. Simpson
DTDiamant Thaçi
Diamant Thaçi
MAMarius Ardeleanu
Marius Ardeleanu
Background Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. Objective The aim was to determine the impact of dupilumab on infection rates in patients with moderate-to-severe AD. Methods This analysis pooled data from seven randomized, placebo-controlled dupilumab trials in adults with moderate-to-severe AD. Exposure-adjusted analyses assessed infection rates. Results Of 2932 patients, 1091 received placebo, 1095 dupilumab 300 mg weekly, and 746 dupilumab 300 mg every 2 weeks. Treatment groups had similar infection rates overall per 100 patient-years (placebo, 155; dupilumab weekly, 150; dupilumab every 2 weeks, 156; dupilumab combined, 152), and similar non-skin infection rates. Serious/severe infections were reduced with dupilumab (risk ratio 0.43; p < 0.05), as were bacterial and other non-herpetic skin infections (risk ratio 0.44; p < 0.001). Although herpesviral infection rates overall were slightly higher with dupilumab than placebo, clinically important herpesviral infections (eczema herpeticum, herpes zoster) were less common with dupilumab (risk ratio 0.31; p < 0.01). Systemic anti-infective medication use was lower with dupilumab. Conclusions Dupilumab is associated with reduced risk of serious/severe infections and non-herpetic skin infections and does not increase overall infection rates versus placebo in patients with moderate-to-severe AD. ClinicalTrials.gov Identifiers NCT01548404, NCT02210780, NCT01859988, NCT02277743, NCT02277769, NCT02260986, and NCT02755649.

30 December 2018 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
DBD.S. Bakker
D.S. Bakker
LAL.F.M. Ariens
L.F.M. Ariens
CLC. Luijk
C. Luijk
JSJ. Schaft
J. Schaft
JTJ.L. Thijs
J.L. Thijs
MBM.S. Bruin‐Weller
M.S. Bruin‐Weller
Click on the article title to read more.

17 February 2021 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
MBM Bruin-Weller
M Bruin-Weller
TBT Biedermann
T Biedermann
RBR Bissonnette
R Bissonnette
MDM Deleuran
M Deleuran
PFP Foley
P Foley
SWS Weidinger
S Weidinger
Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe...